Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,024 GBX | +0.30% | +6.88% | +13.43% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The firm trades with high earnings multiples: 22.09 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.43% | 231B | B+ | ||
+25.99% | 661B | C+ | ||
+26.74% | 566B | B | ||
-6.59% | 352B | C+ | ||
+18.71% | 332B | B- | ||
+3.47% | 283B | C+ | ||
+4.71% | 200B | B- | ||
-9.53% | 195B | A+ | ||
-4.34% | 145B | C+ | ||
-11.15% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC